We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+9.45%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$359M
AUM Growth
–
Cap. Flow
+$346M
Cap. Flow %
96.43%
Top 10 Hldgs %
47.3%
Holding
96
New
96
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$28.5M
2
PFE icon
Pfizer
PFE
+$21.5M
3
XLF icon
State Street Financial Select Sector SPDR ETF
XLF
+$16M
4
MRK icon
Merck
MRK
+$13.4M
5
SHPG
Shire pic
SHPG
+$8.54M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 43.19%
2 Consumer Discretionary 4.33%
3 Technology 3.68%
4 Industrials 3.52%
5 Consumer Staples 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
76
Innoviva
INVA
$1.55B
$1.02M 0.28%
+35,369
New +$1.03M
ELLO icon
77
Ellomay Capital Ltd
ELLO
$270M
$955K 0.27%
+98,953
New +$964K
RNA
78
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$899K 0.25%
+192,428
New +$877K
INSM icon
79
Insmed
INSM
$21.4B
$799K 0.22%
+47,000
New +$720K
SPNS
80
DELISTED
Sapiens International
SPNS
$793K 0.22%
+102,798
New +$702K
IRD
81
Opus Genetics
IRD
$306M
$765K 0.21%
+3,125
New +$660K
RLYP
82
DELISTED
RELYPSA INC COM
RLYP
$750K 0.21%
+30,000
New +$616K
JNJ icon
83
Johnson & Johnson
JNJ
$618B
$714K 0.2%
+7,800
New +$719K
ENTA icon
84
Enanta Pharmaceuticals
ENTA
$366M
$690K 0.19%
+25,292
New +$613K
RIGL icon
85
Rigel Pharmaceuticals
RIGL
$681M
$653K 0.18%
+22,910
New +$672K
ARQL
86
DELISTED
Arqule Inc
ARQL
$626K 0.17%
+291,100
New +$656K
ACHV icon
87
Achieve Life Sciences
ACHV
$659M
$618K 0.17%
+34
New +$597K
HSTO
88
DELISTED
Histogen Inc. Common Stock
HSTO
$565K 0.16%
+438
New +$700K
MACK
89
CALL
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$533K 0.15%
+12,710
New +$368K
MDGL icon
90
CALL
Madrigal Pharmaceuticals
MDGL
$10.8B
$524K 0.15%
+2,857
New +$523K
XNPT
91
DELISTED
XENOPORT, INC.
XNPT
$518K 0.14%
+90,000
New +$487K
GERN icon
92
Geron
GERN
$828M
$474K 0.13%
+105,800
New +$454K
ARWR icon
93
Arrowhead Research
ARWR
$11.9B
$217K 0.06%
+20,000
New +$160K
OCRX
94
DELISTED
Ocera Therapeutics, Inc.
OCRX
$193K 0.05%
+14,881
New +$139K
PTX
95
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$142K 0.04%
+5,650
New +$135K
1 2 3
4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2013 Portfolio in Review

Q4 2013 is the first quarter with a 13F filing on record for Sphera Funds Management, which disclosed 96 positions worth $359M. Its ten largest holdings account for 47% of the portfolio.

Its largest position is GSK: 440,000 shares worth $29.4M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, followed by Consumer Discretionary and Technology.

  • Sphera Funds Management's largest Q4 2013 buy was GSK: 440,000 shares worth $29.4M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $359M portfolio in Q4 2013.
  • Sphera Funds Management disclosed 96 positions in Q4 2013, its first 13F filing on record.

Based on Sphera Funds Management's 13F filing for Q4 2013, filed 13 Feb 2014.